Acquiring Company
BioMarin Pharmaceutical
Acquired Company
Alesta Therapeutics
San RafaelBiotechnologyHealth CareMedicalGeneticsTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
BioMarin Pharmaceutical Inc. has announced its agreement to acquire Alesta Therapeutics for $275 million upfront, with additional payments based on milestones. This acquisition aims to bring Alesta's promising product, ALE1, to market as a potential first oral therapy for hypophosphatasia. The transaction is expected to close this quarter, following customary conditions.
Quick answer
BioMarin Pharmaceutical is acquiring Alesta Therapeutics for $275 million, announced August 18, 2026. BioMarin Pharmaceutical is based in San Rafael, California, United States.
- How much did BioMarin Pharmaceutical pay for Alesta Therapeutics?
- The reported deal value is $275 million.
- What does BioMarin Pharmaceutical do?
- BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery.
- Where are BioMarin Pharmaceutical and Alesta Therapeutics based?
- BioMarin Pharmaceutical is based in San Rafael, California, United States.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Genetics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Aethlon Medical to merge with North Immunology (September 17, 2026)
- Bristol-Myers acquires Medarex for cancer pipeline (August 2, 2026)
- Scipher Medicine to merge with Chemomab Therapeutics (July 8, 2026)
- Chemomab to acquire Scipher Medicine Corporation (July 7, 2026)
- Lifecore Biomedical Announces Merger with Lifecore Inc. (September 27, 2026)
- Dr Lal PathLabs to acquire 70% stake in SN Genelab (September 24, 2026)
Who to call at BioMarin Pharmaceutical, and when
When BioMarin Pharmaceutical changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day BioMarin Pharmaceutical raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioMarin Pharmaceutical, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioMarin Pharmaceutical. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioMarin Pharmaceutical makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Alesta Therapeutics?
Alesta Therapeutics was acquired by BioMarin Pharmaceutical, based in San Rafael. The deal was reported on August 18, 2026. BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. BioMarin Pharmaceutical is publicly traded (BMRN) and operates in Biotechnology.
When did BioMarin Pharmaceutical acquire Alesta Therapeutics?
BioMarin Pharmaceutical's acquisition of Alesta Therapeutics was reported on August 18, 2026. BioMarin Pharmaceutical Inc. has announced its agreement to acquire Alesta Therapeutics for $275 million upfront, with additional payments based on milestones. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Alesta Therapeutics do?
Alesta Therapeutics is a biotechnology company focused on developing therapies for rare genetic diseases. The company is engaged in advancing innovative treatments and conducting clinical trials to find effective solutions for serious health conditions. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.